Supercharged vaccine could offer strong protection with just one dose
By delivering an HIV vaccine candidate along with two adjuvants, researchers showed they could generate many more HIV-targeting B cells in mice.
By delivering an HIV vaccine candidate along with two adjuvants, researchers showed they could generate many more HIV-targeting B cells in mice.
Protein sensor developed by alumna-founded Advanced Silicon Group can be used for research and quality control in biomanufacturing.
The ingestible capsule forms a drug depot in the stomach, gradually releasing its payload and eliminating the need for patients to take medicine every day.
The MESA method uses ecological theory to map cellular diversity and spatial patterns in tissues, offering new insights into disease progression.
Founded by MIT researchers, Senti Bio is giving immune cells the ability to distinguish between healthy and cancerous cells.
New global headquarters will further solidify the company’s pioneering role in the Kendall Square innovation ecosystem.
Starting with a single frame in a simulation, a new system uses generative AI to emulate the dynamics of molecules, connecting static molecular structures and developing blurry pictures into videos.
With models like AlphaFold3 limited to academic research, the team built an equivalent alternative, to encourage innovation more broadly.
Using high-powered lasers, this new method could help biologists study the body’s immune responses and develop new medicines.
Chronic diseases like diabetes are prevalent, costly, and challenging to treat. A common denominator driving them may be a promising new therapeutic target.
Novel method to scale phenotypic drug screening drastically reduces the number of input samples, costs, and labor required to execute a screen.
Large multi-ring-containing molecules known as oligocyclotryptamines have never been produced in the lab until now.
By helping microbes withstand industrial processing, the method could make it easier to harness the benefits of microorganisms used as medicines and in agriculture.
Through academia and industry, Gevorg Grigoryan PhD ’07 says there is no right path — just the path that works for you.
A new gene-silencing tool shows promise as a future therapy against prion diseases and paves the way for new approaches to treating disease.